Method for modifying alimentary behavior and application of pyy or its agonist as a preparation for modifying alimentary behavior

FIELD: medicine.

SUBSTANCE: the present innovation deals with decreasing the intake of calories, the intake of food and appetite in a subject. The method deals, also, with peripheral introduction of therapeutically efficient quantity of PYY3-36 or its agonist, thus, decreasing the intake of calories by a subject. The advantage of the present technique deals with increasing the efficiency in decreasing body weight in such persons.

EFFECT: higher efficiency.

48 cl, 9 dwg, 6 ex

 

Tex descriptions are given in facsimile form.

1. A method of reducing calorie intake, reduce food intake or appetite or increase energy consumption for a subject, characterized in that exercise peripheral introduction to the subject PYY3-36in amounts effective to achieve the physiological levels of PYY3-36determined after a meal, or have peripheral introduction to the subject agonist PYY3-36in a quantity effective to simulate physiological levels of PYY3-36determined after a meal, thus reducing the calorie intake, food intake or decreasing appetite or increasing the power consumption of the entity.

2. The method according to claim 1, characterized in that the subject is overweight.

3. The method according to claim 1, wherein the subject suffers from obesity.

4. The method according to claim 1, wherein the subject suffers from diabetes.

5. The method according to claim 1, characterized in that the peripheral introduction PYY3-36or PYY agonist3-36includes oral, subcutaneous, intravenous, intramuscular, intranasal, dermal, intracisternally, endovaginal, intraperitoneally, the field is, crosslist, buccal, rectal or sublingual introduction or introduction via pulmonary inhalation.

6. The method according to claim 5, characterized in that the dose of PYY3-36or its agonist is from about 45 to about 135 pmol/kg body weight of the subject.

7. The method according to claim 6, characterized in that the dose of PYY3-36or its agonist is approximately 72 pmol/kg body weight of the subject.

8. The method according to claim 1, wherein the PYY3-36or its agonist is administered at least 30 minutes before eating.

9. The method according to claim 1, characterized in that the peripheral introduction PYY3-36or its agonist perform many times, and each dose is administered in an amount of from about 0.5 to about 135 pmol/kg body weight of the subject at least approximately 30 minutes before a meal.

10. The method according to claim 1, wherein the subject is also administered a therapeutically effective amount of an additional agent that suppresses appetite, which is a amfepramone (diethylpropion), phentermine, mazindol, phenylpropanolamine, fenfluramine, dexfenfluramin or fluoxetine.

11. The method according to claim 1, wherein the PYY3-36or its agonist is administered to a subject in amounts effective to reduce the consumption of calories for at least 2 hours

12. The method according to claim 11, wherein the PYY3-36 or its agonist is administered to a subject in amounts effective to reduce the consumption of calories for about 2 to 24 hours

13. The method according to claim 1, wherein the subject is human.

14. The method according to claim 1, wherein the PYY agonist3-36contains a molecule that specifically binds with a Y2 receptor.

15. The method according to 14, wherein the PYY agonist3-36increases the expression of c-fos in the part of the arcuate nucleus in contact with the PYY agonist3-36.

16. The method according to claim 1, wherein the PYY agonist3-36specifically binds to a neuron, containing neuropeptide Y, and inhibits the activity of neurons that contain neuropeptide Y.

17. The method according to item 16, wherein the PYY agonist3-36reduces the pulse frequency of the action potential of a neuron, containing the neuropeptide Y.

18. The method according to item 16, characterized in that the neurons containing neuropeptide Y, synaptic associated with proopiomelanocortin neuron, while the binding of agonist PYY3-36with neurons containing neuropeptide Y, leads to increased activity proopiomelanocortin neuron.

19. The method according to p, wherein the PYY agonist3-36,communicating with neurons containing neuropeptide Y reduces the pulse frequency of the action potential of a neuron, containing the neuro is eptid Y, while the decrease in the activity of neurons that contain neuropeptide Y, leads to increased generation of action potential proopiomelanocortin neuron.

20. The method according to claim 1, characterized in that reach of loss of appetite in the subject.

21. The method according to claim 20, characterized in that reach of the reduction in food intake by the subject.

22. The method according to item 21, wherein achieve reduction of calorie intake by the subject.

23. The method according to claim 1, characterized in that the reach of prevention or reduction of the set of body weight of the subject.

24. The method according to claim 1, characterized in that reach induce or sustain loss of body weight of the subject.

25. The method according to claim 1, wherein the PYY3-36or its agonist is administered in an amount of from about 0.5 to about 135 pmol/kg body weight of the subject.

26. The method according to claim 1, characterized in that reach of inducing or enhancing satiety and feeling of satiety in the subject.

27. The method according to claim 1, characterized in that reach suppress hunger and sensations of hunger in the subject.

28. The method according to claim 1, characterized in that the peripheral introduction to the subject of RUO3-36or its agonist perform repeatedly or in separate doses.

29. The method according to claim 1, characterized in that the peripheral introduction to the subject PYY3-36or its agonist perform perifericos the th injection pulse dose.

30. The method according to claim 1, characterized in that the peripheral introduction PYY3-36or its agonist is carried out in a manner that provides slow, prolonged or controlled release of drugs, or by means of a pump or implantable device for injecting drugs.

31. The method according to claim 1, characterized in that the conduct of the peripheral introduction PYY3-36or agonist at a dose of from about 5 to about 50 nmol.

32. The method according to claim 1, characterized in that the dose of PYY3-36or its agonist is from about 2 to about 20 nmol.

33. The method according to p, characterized in that the dose of PYY3-36or its agonist is approximately 10 nmol.

34. The method according to claim 1, wherein the subject is administered a therapeutically effective amount of an additional agent that suppresses the appetite.

35. The method according to claim 1, wherein the subject is further added at least one agent that reduces the level of glucose in the blood plasma, agents that modify the content of lipids in the blood plasma or agents that reduce food intake.

36. The method according to claim 1, wherein the subject has reached maintain the desired body weight or maintain a desirable body mass index.

37. The method according to claim 1, wherein the subject suffers the violation and the and at risk in respect of breach, a risk factor is obesity or overweight.

38. The method according to claim 1, wherein the subject suffers from disturbance caused by complicated or aggravated due to relatively high nutrient availability.

39. The method according to claim 1, wherein the subject is administered PYY agonist3-36.

40. The method according to claim 1, wherein the subject is administered PYY3-36.

41. The method according to p, wherein the PYY3-36enter the subject in a dose of from about 0.5 to about 135 pmol/kg body weight of the subject.

42. The method according to paragraph 41, wherein the PYY3-36enter the subject in a dose of from about 45 to about 135 pmol/kg body weight of the subject.

43. The method according to paragraph 41, wherein the PYY3-36administered to a subject at a dose of approximately 72 pmol/kg body weight of the subject.

44. The method according to p, wherein the PYY3-36administered in a dose of from 1 to 100 nmol.

45. The method according to claim 1, characterized in that the physiological levels of PYY3-36after a meal ranges from 40 to 60 PM.

46. The method according to item 45, wherein the physiological levels of PYY3-36after a meal ranges from 40 to 50 PM.

47. The use of PYY3-36or its agonist as a means to reduce calorie intake, reduce food intake or appetite or increase energy is gottret the subject.

48. The use of PYY3-36or its agonist as an active ingredient in the production of medicines to reduce calorie intake, reduce food intake or appetite or increase energy consumption at the subject.

Priority items:

24.09.2001 by PP and 48;

10.01.2002 according to claims 1-5, 10, 13-30, 34-40;

28.06.2002 on PP-9, 11, 12, 31-33, 41-46.



 

Same patents:

FIELD: medicine, in particular therapy.

SUBSTANCE: claimed method includes peroral administering of preparation from brown algae at least two time per day. Said preparation represents gel form homogenized brown algae having particle size 500 mum or less and containing at least 15 mg/kg of iodine and carbohydrate fractions: mannat 133.4±12.1 mg/g, alginic acid 147.8±10.7 mg/g. Preparation is administered for 30 min before eating in amount of 1-5 g/kg/day. Daily dose is 50-250 g. Course of treatment is 4-24 weeks.

EFFECT: preparation of increased antioxidant and immunomodulating action.

6 cl, 3 tbl, 6 ex

FIELD: medicine, veterinary science, agriculture, biotechnology.

SUBSTANCE: the present innovation refers to preparations of medicinal and veterinary indication and methods for their obtaining. The suggested complex preparation-probiotic includes a carrier being a porous aluminum oxide-based enterosorbent SUMS-1 and cells of bacteria-eubiotics with nutritive and protective media immobilized upon the mentioned carrier-enterosorbent. The cells of bacteria-eubiotics with nutritive medium are being a lyophilized concentrate of the consortium of either bifidobacteria or lactobacteria, or their mixture at titer being 108-1010 CFU/g, and as a porous carbon-modified enterosorbent SUMS-1 it contains enterosorbent SUMS-1 additionally treated with the solution of metal salt at the following ratio of the preparation components in lyophilized form, weight%: cells with nutritive medium of the consortium of bifido-, or lactobacteria-eubiotics, or their mixture with titer of 108-1010 CFU/g 1.0-10.0; protective medium 0.1-10.0; enterosorbent SUMS-1 additionally treated with the solution of metal salt - the rest up to 100%. Method for obtaining the suggested preparation deals with treating a porous enterosorbent SUMS-1 with the solution of metal salt at volumetric ratio being 1:1, not more and its washing against a reagent with 2-3-fold volumes of distilled water followed by mixing enetrosorbent and bacteria-eubiotics with nutritive and protective media at the ratio of 1:1, not more to keep the mixture till complete immobilization of bacterial cells onto enterosorbent with its subsequent freezing and freeze drying before sterilization. As bacteria one should apply the concentrate of the consortium of bifidobacteria, or lactobacteria, or their mixture at titer being 108-1010 CFU/g. The suggested complex preparation-probiotic provides higher efficiency of sorption and desorption of bacterial cells with enterosorbent SUMS-1 that shows its clinical efficiency and higher colonization activity of bacteria-eubiotics.

EFFECT: higher efficiency.

9 cl, 5 ex, 2 tbl

FIELD: medicine, surgery.

SUBSTANCE: the present innovation refers to treating osseous cavity in patients with chronic post-traumatic osteomyelitis, so, after necrsequestrectomy one should irrigate an osseous cavity with aqueous solution of sodium chloride, then it is necessary to treat the cavity with 3%-hydrogen peroxide solution with subsequent removal of foam with 0.02%-chlorohexidine bigluconate aqueous solution. Then twice during 1 min it is necessary to treat osseous cavity with 0.9%-ozonized sodium chloride solution at ozone concentration being 9000-10000 mgl/l. After that, one should introduce the mixture of anti-infectious chemotherapeutic preparations along with ultrasound cavitation for 3 min at frequency of 40 kHz followed by treating the cavity with the flow of nitrogen monoxide for 5 min at concentration being 5000 mg/cu. m. The innovation enables to increase penetrating capacity of medicinal preparations due to matching the desired mode of cavitary treatment.

EFFECT: higher efficiency of antiseptic treatment.

1 ex

FIELD: biotechnology, molecular biology.

SUBSTANCE: invention proposes a polynucleotide VEGI-192a encoding polypeptide that inhibits growth of human vascular endothelial cells. Invention describes expressing vector comprising polynucleotide and E. coli cell-host comprising vector. Invention discloses polypeptide encoded by polynucleotide and fused protein based on indicated polypeptide. Invention describes polynucleotide encoding fused protein and expressing vector based on indicated polynucleotide. Invention discloses a pharmaceutical composition used for inhibition of angiogenesis based on polypeptide-inhibitor of growth of human vascular endothelial cells and polynucleotide encoding its. Invention describes therapeutic methods for inhibition of angiogenesis and suppression of tumor growth based on this composition. Invention describes an antibody raised to polypeptide that inhibits growth of human vascular endothelial cells. Using this invention provides novel forms of inhibitor of human growth of vascular endothelial cells and can be used in medicine.

EFFECT: valuable biological and medicinal properties of inhibitor.

27 cl, 27 dwg, 13 tbl, 34 ex

FIELD: medicine.

SUBSTANCE: method involves opening pyo-inflammatory focus. Rexod is introduced in addition to basic therapy. Rexod is introduced during the operation or immediately after the operation and then every day once a day intravenously in bolus dose. The drug is introduced during 4-5 days in physiologic saline or in 5% glucose solution at a dose of 0.2 mcg/kg of patient body weight.

EFFECT: enhanced effectiveness of treatment; improved general health state within a short period; reduced oxidation stress; prevented secondary active oxygen forms production.

3 tbl

FIELD: medicine.

SUBSTANCE: disclosed is application of Ximedon (N-(β-oxyethyl)-4,6-dimethyl-1,2-dihydro-2-oxopyrimidine) for treatment and prophylaxis of various intoxication.

EFFECT: preparation of large spectrum of action and inducing effect comparable with Phenobarbital effect.

2 tbl, 13 ex

FIELD: medicine.

SUBSTANCE: method involves treating root canals with instruments and preparation containing calcium hydroxide is temporarily placed into the canals several times changing the portion every 2-5 weeks for fresh one. Before introducing fresh portion, the root canals are treated with antiseptic solution in combination with their ultrasonic treatment.

EFFECT: enhanced effectiveness of treatment; stopped inflammatory responses in periodontium tissues; prevented reinfection.

8 cl

FIELD: medicine, pulmonology.

SUBSTANCE: it is necessary to study initial values of functional reserve ability (FRA) of pulmonary-capillary circulation in %, average pressure value in pulmonary artery (AvPPA) in mm mercury column and daily variability of peak volumetric expiration rate (ΔPVRexp.) in % to calculate the following equation: D=+1.376·FRA-2.087·AvPPA-1.023·ΔPVRexp. At D value being above -25.71 one should predict instable flow of bronchial asthma. The innovation enables to carry out integral evaluation of functional state of pulmonary microcirculation, pressure in pulmonary artery and reactivity of respiratory tract.

EFFECT: higher efficiency and accuracy of prediction.

2 ex

FIELD: pharmaceutical chemistry.

SUBSTANCE: invention provides water-soluble camptotecine derivatives showing excellent therapeutical activity and retarded release suitable for cancer chemotherapy. High-molecular weight camptotecine derivative has structure wherein carboxylic acid group of block copolymer of polyethylene glycol and polymer containing carboxylic acid group in side chain and being acidic amino acid polymer is linked to phenol hydroxyl group of phenolic camptotecines through ester linkage. Also claimed is high-molecular weight camptotecine derivative of general formula (I): . Preparation method comprises combining carboxylic acid group of above-defined block copolymer with phenol hydroxyl group of phenolic camptotecines through ester linkage in presence of condensation agent. Anticancer drug includes above-defined camptotecine derivative and optionally pharmaceutically acceptable carrier.

EFFECT: augmented choice of anticancer drugs.

9 cl, 2 dwg, 2 tbl, 5 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a method for treatment of nicotine dependence in a person using a medicinal formulation with controlled release (MFCR) comprising 5,8,14-triazatetracyclo[10.3.02,11.04,9]hexadeca-2(11),3,5,7,9-pentaene or its pharmaceutically acceptable salt taken in the effective dose, and to a method for reducing adverse effect of this active component. Method involves using MFCR that comprises agents of this active component for its administration to a patient at the rate less about 6 mg/h resulting to administration of at least about 0.1 mg of compound or its salt for 24 h. The initial administration of MFCR results to plasma maximal concentration (Cmax) of active component in average from 10% to 80% of the corresponding Cmax determined for the equal dose of active component in form of bolus with immediate release, and to increasing time of value Cmax in plasma (Tmax) in initial administration in average by 50% relatively to the corresponding Tmax value determined for the equal dose of active component in form of bolus of immediate release. Also, MFCR releases active component in vireo at the rate less 6 mg/h in the dissolving testing using device USP-2 (USA Pharmacopoeia) in order to provide the dissolving time of 50 wt.-% of active component from 1 to 15 h. Indicated agents comprise a tablet with matrix, multi-particles, covered multi-particles or tablet with a cover. Invention provides carrying out the effective treatment of nicotine dependence and without symptoms of adverse effects of active component, in particle, without nausea.

EFFECT: improved method of treatment.

7 cl, 19 tbl, 13 ex

FIELD: biotechnology, molecular biology.

SUBSTANCE: invention proposes a polynucleotide VEGI-192a encoding polypeptide that inhibits growth of human vascular endothelial cells. Invention describes expressing vector comprising polynucleotide and E. coli cell-host comprising vector. Invention discloses polypeptide encoded by polynucleotide and fused protein based on indicated polypeptide. Invention describes polynucleotide encoding fused protein and expressing vector based on indicated polynucleotide. Invention discloses a pharmaceutical composition used for inhibition of angiogenesis based on polypeptide-inhibitor of growth of human vascular endothelial cells and polynucleotide encoding its. Invention describes therapeutic methods for inhibition of angiogenesis and suppression of tumor growth based on this composition. Invention describes an antibody raised to polypeptide that inhibits growth of human vascular endothelial cells. Using this invention provides novel forms of inhibitor of human growth of vascular endothelial cells and can be used in medicine.

EFFECT: valuable biological and medicinal properties of inhibitor.

27 cl, 27 dwg, 13 tbl, 34 ex

FIELD: medicine, biotechnology, pharmaceutical industry.

SUBSTANCE: method involves increasing part of the most active conformation of a glycosylated recombinant protein secreted by mammalian cell by its contact with a reagent for coupled oxidation-reduction. The proposed promotion method of the most active conformation of protein is used in a method for preparing a glycosylated recombinant protein in its the most active conformation. Configuration isomer of protein prepared by the indicated method for preparing a glycosylated recombinant protein in it's the most active conformation used in a method for preparing the protein composition for its administration to user and/or a patient or for consumption by user and/or patient. Using of the proposed invention provides enhancing activity of glycosylated protein prepared by a method of recombinant DNAs using a mammalian cell.

EFFECT: improved preparing method, valuable properties of protein.

27 cl, 9 dwg, 2 tbl, 3 ex

FIELD: chemical-pharmaceutical industry, biochemistry, chemistry of peptides.

SUBSTANCE: invention relates to biologically active latarcin peptides possessing antimicrobial effect that can be used in biotechnology and medicine. Method for preparing antimicrobial latarcin peptides with reduced hemolytic activity by chemical or biotechnological method involves preliminary modeling the space structure of the parent latarcin peptide with high hemolytic activity in its α-helical configuration and change of hydrophobic amino acid residues for hydrophilic residue in the synthesis process when hydrophobic amino acids Ile7 and Phe10 are replaced for hydrophilic amino acids Gln7 and Lys10. After modeling the space structure of the parent latarcin peptide in its α-helical configuration measurement of hydrophobic properties of peptide is carried out additionally and with taking into account the molecular hydrophobic potential value in each point of peptide surface and detection of hydrophobic clusters and amino acid residues localized in them followed by identification of the most effective hydrophilic amino acid residues for using in the synthesis process. Method provides preparing peptides with significantly reduced hemolytic properties and to decrease cytotoxicity of latarcin peptides.

EFFECT: improved preparing method of peptides.

3 tbl, 2 dwg, 6 ex

FIELD: medicine, ophthalmology, pharmacy, preparative biochemistry.

SUBSTANCE: method involves isolation of undamaged lens from fresh enucleated eyes of vertebrate animals. Lenses are kept in an aqueous-saline solution, tissue extract is centrifuged and supernatant is collected. Supernatant is separated by its dissolving in 100% ammonium sulfate solution, dialyzed up to the complete removal of ammonium sulfate ions and separated by isoelectrofocusing method in sucrose gradient density at pH 3.5-10.0. Fractions of acid proteins are collected, dialyzed up to the complete removing sucrose and ampholines and prepared protein aqueous solution is dried and purified by electrophoresis in 7.5-15% polyacrylamide gel. Low-molecular fraction with a value Rf = 0.9-0.95 is eluted from gel with deionized water at temperature 4-7°C for 2-5 days, and prepared fraction is dialyzed in dialysis sacs with penetration limit value of pores 2-8 kDa at temperature 4-7°C for 7-10 days. Prepared regulatory peptide is dried and dissolved in physiological aqueous-saline solution. Invention provides the enhanced percent yield of regulatory peptides possessing biological activity in superlow doses and isolation of highly purified polypeptides of low molecular mass.

EFFECT: improved preparing method.

11 ex

FIELD: medicine, ophthalmology, preparative biochemistry.

SUBSTANCE: method involves isolation of tissue of scleral envelope central region from fresh enucleated eye of vertebrate animals wherein this tissue comprises a clibriform plate. Clibriform plate is washed out, kept in aqueous-saline physiological solution, centrifuged and supernatant is collected. Supernatant is separated by its dissolving in 100% solution of ammonium sulfate, filtered and dialyzed up to the complete removal of ammonium sulfate ions followed by separation by isoelectrofocusing method in sucrose gradient density at pH 3.5-10.0, at temperature 4-6°C and voltage 500-2000 V for 72-96 h. Then fractions of acid proteins are collected, combined and dialyzed up to the complete removal of sucrose and ampholines. Prepared protein aqueous solution is dried up to preparing a dry matter that is purified by electrophoresis method in 7.5-15% polyacrylamide gel and low-molecular fraction with value Rf = 0.9-0.95 containing a regulatory peptide is collected by elution from gel with deionized water at temperature 4-7oC for 2-5 days. Prepared fraction is dialyzed in dialysis sacs with the penetration limit value of pores 2-8 kDa at temperature 4-7oC for 7-10 days with deionized water. After dialysis the regulatory peptide solution is dried again up to preparing flaky-like finely dispersed powder that is dissolved then in physiological aqueous-saline solution. Invention provides the enhanced percent yield of regulatory peptides possessing biological activity in superlow doses and isolation of highly purified polypeptides of low-molecular mass.

EFFECT: improved preparing method.

6 ex

FIELD: virology, biotechnology, medicine, biochemistry.

SUBSTANCE: invention relates to creature agents used in AIDS treatment. Invention proposes pentapeptide of the following structure: Tyr-Pro-Ile-Glu-MeHis of molecular mass 672 Da. Peptide is prepared from sea worm Polychaeta, Eunicidae viscera homogenate extract. Method involves the successive purification by hydrophobic chromatography and reversed-phase high-performance liquid chromatography. Invention expands assortment of natural non-nucleoside inhibitors of HIV reverse transcriptase.

EFFECT: valuable medicinal properties of agent.

3 tbl, 10 dwg

FIELD: medicine.

SUBSTANCE: method involves administering Surfactant BL in discrete small doses in addition to traditional therapy. Dose of 75 mg is dissolved in 2.5 ml of physiologic saline and introduced by means of bronchoalveolar nebulizer within 2 h three times at a dose of 25 mg.

EFFECT: enhanced effectiveness in treating pneumonia; prevented bronchial obstructive syndrome occurrence.

FIELD: medicine.

SUBSTANCE: illustrative compositions include one or several polypeptides of pulmonary tumor, their immunogenic parts, polynucleotides which code such polypeptides, an antigen-presenting cell that expresses such polypeptides, and T-cells being specific to cells that express such polypeptides. The compositions described could be applied, for example, during diagnostics, prophylaxis and/or treating diseases, especially pulmonary cancer.

EFFECT: increased specificity of diagnostics.

11 cl, 10 ex, 5 tbl

FIELD: medicine, ophthalmology.

SUBSTANCE: method involves isolation of macular region of retina pigment epithelium from freshly enucleated eye of vertebrate animals, its washing out in physiological solution, holding pigment epithelium tissue in aqueous-saline solution at 4-70C for 2-4 h followed by centrifugation. Supernatant liquid is collected, its components are separated by isoelectrofocusing method in sucrose gradient density at pH 3.5-10.0. Fractions of basic proteins are collected and sucrose and ampholines are removed by dialysis. Prepared protein solution is dried and purified by electrophoresis on 7.5-15% polyacrylamide gel. Then low-molecular fraction with value Rf = 0.4-0.9 is eluted with deionized water in dialysis sacs with penetration limit of pores 2-8 kDa, and prepared regulatory peptide is dried and dissolved in physiological aqueous-saline solution. Invention provides enhancing percent yield of regulatory peptides possessing the biological activity in superlow doses, and isolation of highly purified polypeptides of low molecular mass.

EFFECT: improved preparing method of medicinal agent.

6 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: method involves isolation of neural retina macular region from freshly enucleated eyes of vertebral animals, washing out and holding retina tissue in aqueous-saline solution followed by centrifugation. Supernatant is collected, its components are separated by electrofocusing method in sucrose gradient density at pH 3.5-10, temperature 4-60C and voltage 2000-5000 V for 72-96 h. Fractions of acid proteins are collected, sucrose and ampholines are removed by dialysis, protein solution is dried and purified by electrophoresis on 5.5-15% polyacrylamide gel followed by elution of a low-molecular fraction with value Rf = 0.7-0.9 from gel with deionized water at 4-70C for 2-5 days, dialysis of the prepared fraction in dialysis sacs with deionized water with penetration limit of pores 2-8 kDa, drying the prepared regulatory peptide and its dissolving in physiological aqueous-saline solution. Invention provides enhancing percent yield of regulatory peptides possessing the biological activity in superlow doses and isolation of highly purified polypeptides of low molecular mass.

EFFECT: improved preparing method of medicinal agent.

7 ex

FIELD: medicine, pediatrics.

SUBSTANCE: the present innovation deals with treating motor-autonomic disorders in children associated with affected function of central nervous system. For this purpose one should puncture perineural areas in the region of the main nervous trunks with alfetin dissolved in cerebrolysine. Additionally, one should puncture in projection area of cervical and lumbar spinal thickenings and areas that correspond to segmentary innervation of organs with affected function and, also, in scalp areas depending upon the character of patient's disorders. The method suggested provides improved autonomic-trophic impact of nervous system.

EFFECT: higher efficiency of therapy.

2 ex

Up!